Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Yao Lin

Showing results (31-40 of 31) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 31 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinomaHo Yeong Lim, Jeong Heo, Hye Jin Choi, et al.
Pageof 4

Showing results (31-40 of 31) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 31 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinomaHo Yeong Lim, Jeong Heo, Hye Jin Choi, et al.
Pageof 4